We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.40 | 203,011 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.30 | 2.50 | 2.40 | 2.40 | 2.40 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 9k | -2.04M | -0.0154 | -1.56 | 3.18M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:08:48 | O | 4,226 | 2.306 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/7/2024 | 07:00 | UK RNS | ValiRx PLC Directorate Changes |
| 03/7/2024 | 18:33 | ALNC |  EXECUTIVE CHANGES: Jadestone Energy's CFO Bert-Jaap Dijkstra to leave |
| 03/7/2024 | 08:51 | UK RNS | ValiRx PLC Proposed Director Appointment |
| 20/6/2024 | 17:56 | UK RNS | ValiRx PLC Result of AGM |
| 19/6/2024 | 11:33 | UK RNS | ValiRx PLC Directorate Change |
| 17/6/2024 | 14:29 | ALNC | IN BRIEF: ValiRx shares up as subsidiary inks contract with US firm |
| 17/6/2024 | 07:00 | UK RNS | ValiRx PLC Inaphaea Contract Award |
| 28/5/2024 | 07:00 | UK RNS | ValiRx PLC Investor Webinar |
| 20/5/2024 | 14:21 | ALNC | ValiRx shares jump as Cytolytix gets Knowledge Transfer Voucher grant |
| 20/5/2024 | 12:00 | UK RNS | ValiRx PLC Business Update |
Valirx (VAL) Share Charts1 Year Valirx Chart |
|
1 Month Valirx Chart |
Intraday Valirx Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 25/7/2024 | 07:14 | VALIRX - A Significantly Undervalued Pharma | 10,391 |
| 25/6/2024 | 16:03 | BITCOIN TRADING | 2 |
| 25/6/2024 | 11:19 | Valirx 24/07/2018 Post GM | 8,414 |
| 16/5/2024 | 08:22 | RAINMAKER'S VALUE THREAD | 8,581 |
| 21/2/2024 | 19:15 | *** Value ONLY *** | 43 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 14:08:50 | 2.31 | 4,226 | 97.45 | O |
| 2024-07-26 13:18:39 | 2.45 | 1,715 | 42.02 | O |
| 2024-07-26 13:18:39 | 2.32 | 1,982 | 46.02 | O |
| 2024-07-26 12:56:54 | 2.43 | 50,000 | 1,215.00 | O |
| 2024-07-26 12:36:12 | 2.43 | 100,000 | 2,430.00 | O |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Valirx Daily Update Valirx Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 2.40p.Valirx currently has 132,348,673 shares in issue. The market capitalisation of Valirx is £3,176,368. Valirx has a price to earnings ratio (PE ratio) of -1.56. This morning VAL shares opened at 2.40p |
Posted at 12/7/2024 11:42 by jasonpugh Email from Adrian.“Hi Jason We are in regular contact with Theormrx. I can understand your point and I understand your frustration. I’m a shareholder too, and like you want the share price to reflect the hard work going on at valirx. As stated in previous news flow we remain confident that Theormrx will complete their funding round soon. Regarding Adam Hargreaves joining the Valirx board that is his decision and the Valirx board fully respect this.” Best wishes Adrian.. |
Posted at 01/7/2024 08:14 by jasonpugh I’ll ask a third time. Will Ambrose activate the option before dec regarding the Val 401 based on Ambrose’s latest release. ???? Because when they do valirx will release an rns to confirm. Will this news increase the share price ?🤦 |
Posted at 30/6/2024 08:02 by jasonpugh @porky aka George Morris.Your last post is misleading. A clarification is in order. Valirx rns dec 5th 2023 regarding Ambrose and 401. Para 3 “….Ambro Now with the latest news from Ambrose regarding 401. On page 11 it details the financial implications of a 4 year plan and the targeting of a five year plan. What porky fails to mention is the five year plan involves cash of £800 mill It clearly states on page 11 regarding 401. NPV of £70mill and peak revenues of £170mill. Go on investopefia and get the definition of NPV (net PRESENT value). Now reread valirx dec 5th 2023 rns. No five years here buddy. Only 12 months which expires in dec Do you think Ambrose are now wanting to execute the option with valirx ? Please DYOR. |
Posted at 28/6/2024 13:04 by porky9 Jason - unless you hold shares in EUDA it doesn’t matter if it’s share price rises bigger than Elon Musks empire, why would they want a two bit, potless additional cash drain on their books that would be an immediate liability when they can use their share price advantage to acquire more assets that are revenue producing.Talk about punters being sold a lemon by the VAL board, bloody hell, sooner Adrian wakes up and cuts this nonsense relationship the better |
Posted at 24/5/2024 16:31 by porky9 look you recently brought in Jason on the spike, by now you should learn how the traders play this game:-You were played yet again like a Stradivarius, in came the ramping crew at 1.8p ramped it, feed some BS, company put out some spin, share price spiked at 3.7p and those that were ahead of the game cashed IN taking a very nice profit with them whilst the suckers were left holding the baby wondering what's hit them as the share price drifts back to 1.8p again. Same old same old.... to clarify Jam tomorrow does not pay a bloated pay roll and benefits to support the boards lifestyles today. |
Posted at 05/4/2024 11:38 by porky9 @lucifier7OK for the purpose of entertainment please educate me as to why you think the business as it stands today is worth more than it’s £5m MCap? My reasoning why it isn’t: MCap was £2.25m in April 21 at its previous restructure yet back then was better positioned and had cash burn under £1.5m 201 is going nowhere, totally neglected and likely superseded, over 15 years old and needs reformulating and new patents, it’s handling a total disaster 301 same and off back of same tech and doing zero. 401 moved to another start up that is trying to get funding for itself to survive being a Phoenix business so little chance of any value there in next 12 months CLX - yes this has potential value I will put it at £1m top side. It needs at least another year dev on it and £400k more to try and position it. So Jam tomorrow for 2025 maybe but won’t be contributing to keep VAL alive short term Labs - what a bloody farce, zero paying customers, decision to buy a load of cell samples sitting in freezers from Imogen that couldn't make its business viable even with 32 staff at its height and the current BOD want to chuck more of your cash at it. I put lab assets at £500k top side if they could find a buyer. So that’s it, I calculate £1.5m of assets at best and a cash burn of £2.5m to feed a load of greedy directors to maintain lifestyles. As cash will likely run out July perhaps the BOD should award themselves a nice big bonus whilst they still have the cash. So please explain how you get a value to justify its current share price? I don’t see it. Even with a new BOD at a penny raise it’s a risk. It’s certainly in a worse place than it was in April 21. I put Share price should be in the region of 1.5p to 1.7p pre 1p Placing IMO |
Posted at 31/1/2024 10:23 by jasonpugh Euda in troubleFor euda to remain in the nasdaq market it must maintain a Mcap of $35mill for 30 consecutive days. After yesterday’s fall its share price is $1.33 per share. What do this equate to in Mcap? According to invest.com the following. Mcap =no of share x share price. Euda=. 24.628mill shares x $1.33= $32.755 mcap. Oh dear 🤦a So what is the minimum requirement for share price to reach for 30 consecutive days? A. $35mill divided by number of shares(24.628) = $1.42 per share. Oh dear. 9p deficit lol 🤦a |
Posted at 18/1/2024 12:54 by porky9 Also, if any of the perma bulls around would like to challenge me on my valuation comments I would welcome that if I have overlooked something? I seriously don’t see this business valued at anything remotely near the £7.35m the current value, the 5.5p Share Price – you are literally buying the “Emperor’Let me break it down: - 1. Inaphaea labs – This is now what this business is all about. Suzy’s pet project. So, you have a start up lab business eating cash led by directors that have NEVER built or scaled a business from ground up. The model is highly labour intensive. They have three scientists. Imogen at its height had over 36 staff and still couldn’t make it viable. Now they want to waste £600k of your cash expanding the Imogen Biobank and £200k on developing the lab brand – that’s half the cash raised in this lab!!! Yet they can’t make what they have pay? I will be interested to see what the three months contract they won was worth when they issue to results to the end of December, I suspect it was a token fee. As I see it, its going to take a heck of a lot of time and more cash to establish this lab and investors did not sign up for that, the BOD took them down this path. Most UK labs are loss making, the best in the market can only deliver up to a 20% return due to its a highly labour-intensive model. Valirx would probably need something like north of £10m revenue to generate gross profits to cover existing overheads and that’s assuming no increase in head count. 2. Stingray – So another £100k of cost and won’t know until after November 24 end of current evaluation phase. So, lets call that WIP for a year plus. No immediate cash return if ever. Then we move onto the main assets the Clinical Stage Assets: - 3. 201 – well IMO forget it, now over 14 years old and still awaiting on THX. They won’t execute the LOI but those still with faith in Suzy will need to allow it to run its course. By end of June AGM, the penny should finally drop. It’s a total dead duck. So zero revenue from here. 4. 401 – why that was handed to another business heaven knows, clearly VALs lab lacked the experience to take it inhouse but another start up with effectively an LOI that won’t get executed. So, no value here either, certainly not in the next year if ever. Then we move to pre-clinical assets: - 5. CLX – well they are spending 200k more on it and it needs another year of work plus so you will be waiting a good while on that one. It has potential IMO I like it but years off anything to deliver a financial return. 6. VAL 301 – again some of the 200k being spent on that. Its so outdated now that it will need all its IP patents revising and updating so that one is years off, if ever IMO with more cost on it but with it being 14 years old like 201 is it worth it now? Who’s knows but certainly no financial return anytime soon. 7. BC201 – no idea, was going to do something with covid a while back, missed opportunity anyhow as I see it. No follow up and badly managed like the other assets IMO. 8. AND finally we have £200k earmarked for new evaluations. Well previously they ignored new evaluations to focus on the start up lab and anything found now is at least a year away from being taken to the next stages. So no value here yet either. So, as you can see there is next to nothing here worth investing in. How they got the recent placing away at this eye watering valuation is beyond me. The entire board are culpable for the dire decisions made here and frankly they all need replacing IMO before this becomes even remotely investable. The share price will continue to drift until the changes are made. Come September they will be looking to raise again. 17 raises, three 125:1 consolidations and ZERO revenue excepting that 3 month lab contract – how have they got away with this? Unfortunately, i believe we are stuck in this limbo until the AGM when BOD positions come up for election - hopefully the change will then come. Until then IMO AVOID |
Posted at 04/1/2024 02:36 by porky9 I could be wrong but i highly suspect that Adam sold down from 14p hype bubble in order to support the placing at 6p giving the company more cash to squander whilst trying to maintain this ridiculously bloated over priced market cap. We will know for certain once the declared positions are confirmed.No way on this planet is this business worth £ 8.4m fully diluted 140m shares at 6p should all resolutions get passed today. No way. They can try and pump both 201 and 401 as deals with LOI's in progress but both are worth jack sh1t as neither will be executed imo. Further, labs will take years and buckets of further cash to establish. Its so labour intensive and a real cash drain. This really is buying the Emperors New Clothes, there is FA here now left of any value. Punters are seriously deluded if they think EUDA with THX are going to raise north of £20m to cover phased trials for a 14 year old 201 candidate AND give VAL a chunk of cash on the table. Forget it. The mcap was £2.25m back in April 21 restructure, the outlook was better then than it is now. Cash burn is way out of control again and all that will happen now is they will spend the lot and be back for more in September and the cycle will repeat. But SH have helped create this situation by supporting this placing at this ridiculous false level value. A number in this placing are expecting to manipulate a pump, sucker some newbies in to get out on a spike with a profit. Not going to work. Sorry but IMO the share price is going to drift back down to the £2m mcap at best due to the placing price being too high. Hence why Suzy would only risk £4k of her own cash despite earning £160k plus benefits. Some here really need to wake up. Once the nonsense with 201 is fully exposed you can totally write the share price off, the share price is only holding up at this silly level whilst hopeium remains that THX are going to complete on 201 - They wont IMO. The ONLY thing that can change this situation is a total board clear out of the dead wood and its looking like its going to be the end of June AGM before you get that chance again and even then it wouldn't surprise me if Adam votes to keep them all in situ again - talk about doing the same thing and expecting a different result - total madness. Sorry but the stock remains totally uninvestable |
Posted at 03/1/2024 08:47 by neotheone Very likely the TRX merger is DOA.If this is confirmed then its game over for the Val share price. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
